Background: Treatment with nasal high-flow therapy has efficacy similar to that of nasal continuous positive airway pressure (CPAP) when used as postextubation support in neonates. The efficacy of high-flow therapy as the primary means of respiratory support for preterm infants with respiratory distress has not been proved.
Methods: In this international, multicenter, randomized, noninferiority trial, we assigned 564 preterm infants (gestational age, ≥28 weeks 0 days) with early respiratory distress who had not received surfactant replacement to treatment with either nasal high-flow therapy or nasal CPAP. The primary outcome was treatment failure within 72 hours after randomization. Noninferiority was determined by calculating the absolute difference in the risk of the primary outcome; the chosen margin of noninferiority was 10 percentage points. Infants in whom high-flow therapy failed could receive rescue CPAP; infants in whom CPAP failed were intubated and mechanically ventilated.
Results: Trial recruitment stopped early at the recommendation of the independent data and safety monitoring committee because of a significant difference in the primary outcome between treatment groups. Treatment failure occurred in 71 of 278 infants (25.5%) in the high-flow group and in 38 of 286 infants (13.3%) in the CPAP group (risk difference, 12.3 percentage points; 95% confidence interval [CI], 5.8 to 18.7; P<0.001). The rate of intubation within 72 hours did not differ significantly between the high-flow and CPAP groups (15.5% and 11.5%, respectively; risk difference, 3.9 percentage points; 95% CI, -1.7 to 9.6; P=0.17), nor did the rate of adverse events.
Conclusions: When used as primary support for preterm infants with respiratory distress, high-flow therapy resulted in a significantly higher rate of treatment failure than did CPAP. (Funded by the National Health and Medical Research Council and others; Australian New Zealand Clinical Trials Registry number, ACTRN12613000303741 .).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMoa1603694 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-flow nasal cannula oxygen therapy versus non-invasive ventilation in healthy respiratory physicians: a non-randomized study.
Front Med (Lausanne)
January 2025
Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.
Background: High-flow nasal cannula (HFNC) and non-invasive ventilation (NIV) are commonly used for respiratory support. This study aims to first establish whether to use HFNC or NIV based on comfort levels, and subsequently evaluate diaphragmatic function under equivalent comfort levels to determine the optimal modality for clinical application.
Methods: A self-controlled, non-randomized study was conducted with 10 healthy respiratory physicians as participants.
Study of Children Aged Under 2 Years Admitted With RSV at Four Australian Hospitals [2021-2022].
J Paediatr Child Health
January 2025
WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Doherty Institute, Melbourne, Victoria, Australia.
Aims: Primary aim was to review severe acute respiratory infections (SARI) hospitalisations caused by respiratory syncytial virus (RSV) in children aged < 2 years in paediatric hospitals in Australia. Secondary aims included RSV subtyping, assessing RSV seasonality and contributing to the World Health Organisation's RSV surveillance programme.
Methods: We prospectively reviewed the medical records of children (< 2 years of age) with a confirmed SARI who were admitted to one of four major Australian paediatric hospitals and had a respiratory sample analysed by Polymerase Chain Reaction (PCR).
Impact of Surgical Mask Placement Over High-Flow Nasal Cannula on Oxygenation Parameters in COVID-19 Patients Experiencing Hypoxemic Respiratory Failure.
Cureus
December 2024
Department of Emergency Medicine, MGM Medical College and Hospital, Navi Mumbai, IND.
Background: During the COVID-19 pandemic, managing respiratory failure in critically ill patients has presented significant challenges. A high-flow nasal cannula (HFNC) has been established as an effective respiratory support modality, offering heated, humidified oxygen at high flow rates. However, concerns persist regarding the potential for aerosol dispersion and the risk of viral transmission, particularly in COVID-19.
View Article and Find Full Text PDFHygrometry behavior during high-flow nasal oxygen therapy and non-invasive mechanical ventilation: A narrative review of bench to clinical studies.
J Intensive Med
October 2024
Intensive Care Unit, Hospital Morales Meseguer, Murcia, Spain.
Recently, there has been growing interest in knowing the best hygrometry level during high-flow nasal oxygen and non-invasive ventilation (NIV) and its potential influence on the outcome. Various studies have shown that breathing cold and dry air results in excessive water loss by nasal mucosa, reduced mucociliary clearance, increased airway resistance, reduced epithelial cell function, increased inflammation, sloughing of tracheal epithelium, and submucosal inflammation. With the Coronavirus Disease 2019 pandemic, using high-flow nasal oxygen with a heated humidifier has become an emerging form of non-invasive support among clinicians.
View Article and Find Full Text PDFUtilization of High-Flow Nasal Cannulas in Pediatric Critical Care: A Single-Center Experience.
Cureus
December 2024
Pediatric Intensive Care Unit, King Fahad Medical City, Riyadh, SAU.
Background: High-flow nasal cannula (HFNC) therapy has developed as a valuable tool for respiratory support in pediatric critical care. It offers an intermediate level of support between traditional low-flow oxygen and non-invasive ventilation (NIV). Studies suggest its effectiveness in improving oxygen delivery, work of breathing, and secretion clearance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!